CapitolRadar tracks every publicly disclosed REGN trade by US congress members and corporate insiders: 53 disclosed trades (25 buys, 28 sells) by 3 tracked traders, from 2019-09-20 to 2026-09-04. Updated daily from official filings.
Want a ping when Congress buys REGN? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Regeneron Pharmaceuticals, Inc. (REGN) — Healthcare · Biotechnology, market cap about $80.2B.
CapitolRadar analysis
49 trades split almost evenly between buys and sells
49 tracked REGN trades comprise 24 buys and 25 sells from three distinct traders between May 27, 2020 and July 7, 2026. The one-trade difference leaves the full-period activity close to balanced by transaction count, with buys representing just under half of the records. Because the sample includes only three traders, the totals are concentrated and should not be treated as broad congressional sentiment toward Regeneron Pharmaceuticals or the biotechnology industry.
12 listed quarterly trades show intermittent activity
12 trades appear across the eight specified quarters. The busiest listed period was 2024 Q4, with three trades and no buys. Both 2024 Q3 and 2025 Q3 recorded two trades; each included one buy. The remaining listed quarters had one trade apiece: 2024 Q2, 2025 Q1 and 2026 Q1 were sells, while 2026 Q2 and 2026 Q3 were buys. These quarter-level counts are small, so changes from one period to another can reflect a single transaction rather than a sustained pattern.
16 of 24 buys came from Ro Khanna
Ro Khanna accounted for 16 buys, or two-thirds of all tracked purchases, with the latest dated July 7, 2026. Josh Gottheimer recorded six buys, last dated July 11, 2023, and Tommy Tuberville recorded two, last dated April 3, 2023. Two of these three buyers also purchased each of FCX, ADI, NOW, PANW, APD and GOOGL. That overlap identifies shared holdings among a very small group; it does not establish coordination or a common rationale.
Congressional transaction disclosures may be filed up to 45 days after a trade, so the public record can lag the underlying activity. Reported transaction amounts are typically disclosed as ranges, making any dollar-value totals estimates rather than exact figures; no amount ranges are provided here. Trade counts also give equal weight to transactions regardless of size.
Analysis written from the tracked record on 2026-09-01; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 2 | 1 | 1 |
| 2026 Q2 | 1 | 1 | 0 |
| 2026 Q1 | 1 | 0 | 1 |
| 2025 Q3 | 2 | 1 | 1 |
| 2025 Q1 | 1 | 0 | 1 |
| 2024 Q4 | 3 | 0 | 3 |
| 2024 Q3 | 2 | 1 | 1 |
| 2024 Q2 | 1 | 0 | 1 |
Who is buying REGN?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 16 | 2026-07-07 | — |
| Josh Gottheimer | 7 | 2023-07-11 | — |
| Tommy Tuberville | 2 | 2023-04-03 | — |
Disclosed trades in REGN
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-04 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2026-07-07 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2026-04-13 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2026-01-29 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-09-29 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-08-26 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-01-24 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-11-29 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-11-19 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-10-23 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-09-09 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-07-01 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-04-04 | Tommy Tuberville | sell | $1,001 - $15,000 | — |
| 2024-02-08 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-01-10 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-11-13 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2023-11-03 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-10-02 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-08-29 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-08-03 | Ro Khanna | sell | $1,001 - $15,000 | — |
CapitolRadar signal history
NEW PICK 2026-08-26
Rep. Ro Khanna disclosed a $1,001–$15,000 purchase of Regeneron stock, while one company officer also bought shares. The panel passed mainly because Khanna has no scored 30- or 90-day trade history, so there is no evidence that his disclosures have been a reliable signal. A meaningful record of prior trades with positive excess returns would have supported a different verdict; the 36-day reporting delay also limits how timely this signal is.
These buyers also bought
Other stocks the tracked buyers of REGN disclosed buying in the last six months: AMD (2) · ADI (2) · SNDK (2) · MSFT (2) · RSG (2) · GOOGL (2).
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic derma…
Frequently asked questions
Which politicians bought REGN most?
Ro Khanna leads with 16 disclosed buys, followed by Josh Gottheimer.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.